Board summary
Key figures
42,188
Registered population
60.6% aged 18–64
20.8%
Aged 65+
ICB 21.9% · England 17.9%
9.2%
Ethnic minority (non-White)
4.2% Asian · England 9.6%
4.2%
In IMD quintile 1
ICB 9.2% · England 21.0%
~1,738
Core20 residents (est.)
Resident basis; registered basis ~1,898 · see page 3
7,348
Hypertension register
+5.31% in 3 yrs · England +5.60%
546
SMI register
34.1% of Worthing's
783
COPD register
Reviews +6.24% in 3 yrs
Forecast to 2030
8,285
Hypertension patients, 2030
+937 on today
70.8%
QRISK ≥20% on statins, 2030
+3.94pp over 3 yrs
6.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure reviews fell over three years.
Reviews fell 4.9% from 2023 to 2025 (England +8.7%), leaving current coverage at 75.5% against 78.5% in England, which may reflect recall gaps.
Smoking cessation offers dropped against England.
Offers fell 5.8 pp from 2023 to 2025 (England +0.1 pp) to 92.0% (England 94.2%), with Broadwater Medical Centre at 75.6%.
Mental health blood pressure checks exceed comparators.
Annual blood pressure checks on the severe mental illness register reached 87.0% (England 83.4%, ICB 81.3%) after rising 10.5 pp (England +4.4 pp).
Population, age and ethnicity
Older residents comprise 20.8% of the list alongside 71 catchment care homes
Central Worthing Practices PCN registers 42,188 patients across three practices. Patients aged 65+ represent 20.8% (8,756 patients), below Worthing (22.1%) and NHS Sussex ICB (21.9%), but above England (17.9%). The 0–17 cohort comprises 18.6% (7,846 patients; Worthing 17.4%, ICB 17.7%, England 19.6%), and ages 18–64 account for 60.6% (25,586 patients). Usual residents are 90.8% White (Worthing 91.4%, ICB 91.0%, England 81.1%), leaving a 9.2% ethnic minority share; ethnicity reflects Census area estimates rather than GP records. Projected population growth to 2030 is 1.4% (Worthing 1.9%, ICB 2.1%, England 2.3%), though projection methodology remains unverified.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Worthing local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Worthing LA) | 2,490 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Worthing LA) | 1,480 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Worthing LA) | 15.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Overall deprivation is low but Core20 patients concentrate in two practices
The PCN Core20 cohort is 4.2%, below Worthing (4.4%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%), with an average IMD decile of 6.5 (England 5.5). Weighted practice share models at 4.5%, showing a minor reconciliation difference against the PCN rate. Across an 8.9 pp practice range, Victoria Road Surgery has an 8.9% Core20 share (1,251 estimated patients) and Broadwater Medical Centre has 5.6% (647 estimated patients), while St. Lawrence Surgery records 0.0%. This distribution indicates proactive reviews could be prioritised where deprived cohorts concentrate.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
546
SMI register
1.29% recorded prevalence
310
Learning disability register
0.73% recorded prevalence
71
Care homes, 1,829 beds
In the PCN catchment
9.0%
Provide unpaid care
Worthing, Census 2021
Recorded severe mental illness prevalence is 1.3% (546 patients; Worthing 1.3%, NHS Sussex ICB 1.1%, England 1.0%), and learning disability prevalence is 0.7% (310 patients; Worthing 0.7%, ICB 0.6%, England 0.6%). The PCN catchment encompasses 71 care homes containing 1,829 beds. Crude register prevalence slightly above England reflects recorded diagnoses rather than unmet need, and catchment bed capacity does not establish registered care-home resident counts.
Severe mental illness: physical health checks
SMI checks reached 87.0% for blood pressure (England 83.4%) and 84.5% for BMI (England 82.1%). Smoking cessation offers were 92.0% (England 94.2%), with Broadwater Medical Centre recording 75.6%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,348
Hypertension register
+5.31%
Register growth, 3 yrs
Worthing +3.32% · England +5.60%
+3.67pp
BP control, under 80
≤140/90 · +2.44pp aged 80+
+937
More patients by 2030
Forecast 8,285 (19.21%)
Hypertension case-finding and control
Hypertension recorded QOF prevalence is 17.3%, below Worthing (17.4%), but above NHS Sussex Integrated Care Board (16.3%) and England (15.2%).
Lipids and statins
For patients with QRISK at or above 20%, 62.1% receive lipid-lowering therapy, below England (63.6%) but above Worthing (57.8%) and NHS Sussex Integrated Care Board (60.0%). Statin coverage for diabetes primary prevention is 72.3%, below England (73.2%) and matching NHS Sussex Integrated Care Board (72.3%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 85,725 | £2.00 | £2.42 | £1.86 | £171,450 |
| Cardiovascular (all), 2025 | 106,508 | £3.52 | £3.32 | £3.33 | £374,908 |
In 2026, the PCN prescribed 85,725 lipid-regulating drug items at £2.00 each (£171,450 spend), compared to £1.86 in England, £2.24 in Worthing, and £2.42 across NHS Sussex Integrated Care Board, spending £12,002 more than at England's unit cost across 85,725 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.39%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.37%
Asthma prevalence, PCN 3-yr % change
Asthma recorded prevalence is 8.0% (England 6.6%) and COPD prevalence is 1.9% (England 1.9%). Annual reviews reached 70.1% for asthma (England 65.7%) and 80.7% for COPD (England 76.4%), though an estimated 955 asthma patients lacked a recorded review. Second-hand smoke status recording for asthma patients aged 6–19 was 72.4% (England 78.8%), with Broadwater Medical Centre at 52.9%. Prescribing for asthma management was 1,432 items per 1,000 population aged 5–19 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 4.9% (England 3.8%). In childhood immunisations, age-5 uptake exceeds England (MMR dose 2 at 92.2% vs 82.8%; 4-in-1 booster at 90.0% vs 80.9%) but misses the 95% target. A 43.5 pp practice spread in QOF vaccination achievement and a 7.7 pp MMR dose difference at St. Lawrence Surgery indicate uneven delivery, meaning preschool booster call-recall requires proactive coordination.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) and up +5.0 pp since 2013, but 16.5 pp below the 75.0% national ambition (about 1,360 extra early-stage cases needed). Known-stage completeness was 64.3% (8,209 of 12,766; England 67.0%); staging reflects system pathways, not PCN performance. At PCN level, recorded cancer prevalence is 4.9% (England 3.8%), rising +11.4% over three years (England +9.0%). PCN screening coverage is 77.9% for breast (England 69.9%) and 71.7% for cervical (England 66.8%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day standard, 19.8 pp below the 85.0% standard and trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%). Its 31-day treatment performance was 76.8% (standard 96.0%; ICB 90.4%), and 28-day faster diagnosis was 74.0% (England 79.3%). Across provider diagnostics, 12.9% waited 6+ weeks, with 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy (England 30.8% and 32.1%); this reflects provider waiting times, not PCN performance.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). Provisional experimental community data for June 2026 recorded 115,485 care activities and 78,050 care contacts for West Sussex residents, alongside 316,320 activities and 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Contacts with adults aged 65 and over accounted for 72.7% of West Sussex resident contacts (56,740 of 78,050); this reflects wider borough activity rather than PCN-level service use.
Practice variation and patient experience
Vaccination achievement and Core20 share diverge across the three practices
In 2025/26, clinical QOF achievement was 100.0% at St. Lawrence Surgery, Victoria Road Surgery, and Broadwater Medical Centre (England 97.1%). Vaccination achievement spanned 43.5 pp, from 53.5% at Broadwater Medical Centre to 97.0% at Victoria Road Surgery (England 55.2%). Overall QOF achievement reached 94.7% at Broadwater Medical Centre and 99.7% at Victoria Road Surgery (England 92.5%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St. Lawrence | 126 | 0.0 | 57.6% | 83.7% | 91.5% |
| Victoria Road | 91 | 8.9 | 40.0% | 68.6% | 87.2% |
| Broadwater | 94 | 5.6 | 41.1% | 62.3% | 68.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 4.9% over three years against England's +8.7% growth
Over three years, heart failure reviews fell 4.9% (England +8.7%, NHS Sussex Integrated Care Board +4.5%), leaving current coverage at 75.5% against England's 78.5%. Smoking cessation offers dropped 5.8 pp (England +0.1 pp) to 92.0% (England 94.2%). Conversely, severe mental illness monitoring showed gains: alcohol recording rose 14.6 pp (England +5.4 pp), blood pressure checks gained 10.5 pp (England +4.4 pp), and BMI recording climbed 8.7 pp (England +5.1 pp). In addition, dementia register growth reached +16.4% (England +6.0%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Smoking support (SMI)
Learning disability register
COPD register
Hypertension BP reading
Alcohol record (psychosis)
BP check (SMI)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Worthing | Asset | PCN | Worthing |
|---|---|---|---|---|---|
| Care homes (catchment) | 71 (1,829 beds) | n/a | Schools (catchment) | 43 | n/a |
| Children's centres | 5 | 7 | Places of worship | 37 | 48 |
| Libraries | 3 | 5 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 10 | 13 | Primary academies | 8 | 8 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Smoking cessation and asthma smoke recording
Smoking cessation offers are 92.0% (England 94.2%), falling 5.8 pp over 2023 to 2025 (England +0.1 pp), with Broadwater Medical Centre at 75.6%. For discussion: audit clinical templates and run targeted recall for smoking cessation offers and child asthma smoke exposure recording, starting at Broadwater Medical Centre. Low cost, quick to run.
Option 2
Heart failure reviews and register check
Heart failure reviews are 75.5% (England 78.5%) after falling 4.9% (England +8.7%). The 474-patient register (1.1%) has a modelled gap of -11 to +37 against England (1.1%) and Worthing (1.2%). For discussion: run structured recall for overdue annual heart failure functional reviews and audit register coding in Core20 practices. Moderate effort to run.
Option 3
CVD lipid therapy and stroke coding
Lipid therapy for QRISK >= 20% is 62.1% (England 63.6%). Recorded stroke prevalence is 2.0% (858 patients; Worthing 2.4%, England 1.9%), a modelled gap of -61 to +156. For discussion: run pharmacist-led recall for patients with QRISK >= 20% or diabetes off statins, and audit hospital discharge stroke coding. Moderate effort to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home MDT capacity (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Targeted Core20 clinical review outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted smoking cessation outreach (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Preschool booster recall review (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening equity audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Smoking cessation and asthma smoke recording (p12) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | — | PCN & Practice |
| Option 2 · Heart failure reviews and register check (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Option 3 · CVD lipid therapy and stroke coding (p12) | Stroke register · Stroke: QOF prevalence · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
